A 35-year-old woman presents with a 2-year history of easy bruising, epistaxis, and prolonged bleeding after dental procedures. Platelet count is 45,000/μL. Bone marrow examination shows normal megakaryocytes. Which investigation is most appropriate to differentiate immune thrombocytopenia (ITP) from drug-induced thrombocytopenia?

## Investigation of Choice for Immune Thrombocytopenia ### Clinical Context This patient has: - Thrombocytopenia (45,000/μL) - Normal bone marrow megakaryocytes (rules out production defect) - Clinical features of bleeding disorder The differential includes immune-mediated destruction vs. drug-induced immune thrombocytopenia. ### Why Antiplatelet Antibody Detection is Correct **Key Point:** Antiplatelet antibody detection (PAIgG/PAIgM) is the most specific investigation to confirm immune-mediated platelet destruction in ITP. It identifies circulating IgG or IgM antibodies bound to platelet surfaces or in serum, confirming the autoimmune mechanism. **High-Yield:** PAIgG detection has ~80% sensitivity and ~90% specificity for ITP. A positive result strongly supports immune-mediated destruction rather than drug toxicity or other causes. **Clinical Pearl:** In drug-induced immune thrombocytopenia, antiplatelet antibodies are also present but the clinical history (temporal relationship to drug exposure) and antibody specificity (often drug-dependent) help differentiate it from primary ITP. ### Diagnostic Algorithm for Thrombocytopenia ```mermaid flowchart TD A[Thrombocytopenia]:::outcome --> B{Bone marrow megakaryocytes?}:::decision B -->|Decreased| C[Production defect]:::outcome B -->|Normal/Increased| D{Bleeding signs?}:::decision D -->|Yes| E[Immune or consumptive?]:::decision E -->|Immune suspected| F[PAIgG/PAIgM detection]:::action F -->|Positive| G[ITP or drug-induced immune]:::outcome E -->|Consumptive| H[PT, aPTT, fibrinogen, D-dimer]:::action ``` ### Why Other Investigations Are Inferior | Investigation | Limitation | Why Not First-Line | |---|---|---| | Flow cytometry for platelet surface antigens | Detects abnormal glycoproteins (Bernard-Soulier, Glanzmann thrombasthenia) | Not useful for immune-mediated destruction; patient has normal platelet morphology | | Platelet aggregation studies | Assesses platelet function (adhesion, aggregation) | Abnormal in functional platelet disorders, not in ITP where platelets are destroyed | | Bleeding time | Crude test of platelet function; poor standardization | Obsolete for diagnosis; does not differentiate immune from non-immune thrombocytopenia | **Warning:** Bleeding time is no longer recommended by major guidelines (ACCP, ASH) for evaluation of bleeding disorders due to poor sensitivity and specificity.